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Summary Piritrexim is a lipid-soluble inhibitor of dihydrofolate reductase (DHFR) that enters tumour cells
rapidly by passive diffusion, cannot be polyglutamated, and is as effective as methotrexate in inhibiting
DHFR. Bioavailability after oral dosing is approximately 75%. We performed a phase II study with oral
piritrexim in non-chemotherapy pretreated patients with metastatic urothelial cancer.
Thirty-three patients were treated with 25 mg three times daily for 5 consecutive days, repeated weekly, witfl
provision for dose escalation or reduction according to the toxicity observed.
Of 29 evaluable patients, one patient achieved a complete response of 19+ weeks duration, and ten patients
achieved a partial response with a median duration of 22 weeks (range 16-48), for a total response rate of
38%. Piritrexim was generally well tolerated, with myelosuppression as the major toxicity, that frequently
required dose modification.
We conclude that piritrexim appears to be an active agent in patients with metastatic urothelial cancer when
administered as a 5-day, low-dose oral schedule. It would be attractive to investigate the combination of
piritrexim and cisplatin.
Piritrexim (2,4 - diamino - 6[2,5 - dimethoxybenzyl] - 5 - methyl
pyrido - [2,3d] pyrimidine; PTX) is a new, lipid-soluble dihydro-
folate reductase (DHFR) inhibitor (Duch et al., 1982; Sed-
wick et al., 1982; Sigel et al., 1987). The drug differs from
methotrexate (MTX) in that it crosses membranes rapidly by
passive diffision and cannot be polyglutamated, therefore the
intracellular levels are expected to parallel plasma levels in
highly perfused tissues. PTX is as potent as MTX in vitro as
an inhibitor of DHFR. Bioavailability after oral dosing is
approximately 75% (Weiss et al., 1989). The relatively short
half-life (3 to 5 h) and the lack of polyglutamation of PTX
makes a continuous administration of this agent attractive.
Consequently, phase I and II studies of PTX were conducted
using prolonged, low-dose oral schedules (Feun et al.,
1991a,b). Myelosuppression proved to be dose-limiting. Anti-
tumour activity was observed in patients with malignant
melanoma and urothelial cancer (Weiss et al., 1989; Feun et
al., 1991a,b). The recommended dose for further phase II
studies was 25 mg three times a day for 5 days (Feun et al.,
1991b). We performed a phase II study with oral PTX in
non-chemotherapy pretreated patients with metastatic
urothelial cancer.
Patients and methods
Patients
Eligibility criteria required histologically proven transitional
cell carcinoma of the urinary tract, measurable distant metas-
tases or measurable pelvic tumour not amenable to loco-
regional treatment, performance status (WHO Scale) 0-2,
serum creatinine below 140;Lmol 1-', bilirubin below 25timol
1-1, white blood cells (WBC) above 4 x I091' and platelets
above 100 x 1091-'. Patients with prior systemic chemo-
therapy, irradiated indicator lesions or brain metastases, or
with poor medical risk were excluded.
Study design
PTX was administered orally at a dose of 25 mg three times
daily for 5 days, repeated weekly. The drug was administered
1 h before meals or 2 h after meals. There was a provision
for dose escalation to 25 mg four times daily for 5 days if no
toxicity after a set of four cycles had been encountered. The
dose was unchanged if grade 1 myelotoxicity had been exper-
ienced in a set of four cycles. There was a dose delay in case
of WHO grade 2 myelotoxicity within the first 3 weeks, and
grade 3/4 at any time. After recovery, treatment was resumed
with 25 mg three times daily for 4 days (one step), with
provision for a second dose reduction to 25 mg twice daily
for 4 days (second step). Patients were seen weekly at the
outpatient clinic in order to document adverse events and to
make dose adjustments. Measurement of the indicator
lesion(s) was performed every 4 weeks. Response was assess-
ed according to WHO criteria; a complete response (CR) was
defined as the complete disappearance of all known disease,
determined by two observations not less than 4 weeks apart;
partial response (PR) as at least 50% reduction in the sum of
the products of the two largest perpendicular diameters of all
measurable lesions, determined by two observations not less
than 4 weeks apart; progressive disease (PD) as an increase
of at least 25% in any measurable lesion or the appearance
of a new lesion; and no change (NC) as less than 50%
reduction in total tumour volume or less than 25% increase
in any measurable lesion. Response duration was calculated
from the start of chemotherapy to the date of first observa-
tion of progressive disease.
In case of response (CR/PR), patients continued treatment
until progression. In case of PD at 4 or 8 weeks, patients
went off study, and were offered the option of cisplatin
combination chemotherapy. Patients were evaluable for res-
ponse if they had completed 8 weeks of treatment, unless
there was progression at 4 weeks. All patients who had
received at least one dose of chemotherapy were evaluable
for toxicity, which was also graded according to WHO
criteria.
Institutional review board-approved informed consent was
obtained for all patients before study entry.
Results
Thirty-three patients were entered into the study. Patients
characteristics are shown in Table I. Four patients were not
evaluable for response: one patient was diagnosed to have a
second primary (lung) during the course of treatment, and
three patients stopped before 4 weeks due to toxicity (one
patient had grade 4 leucopenia after 3 weeks and two
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Table I Patient characteristics
Number of patients entered 33
Sex (male/female) 22/11
Age median (range) 65 (41-76)
WHO Performance Score 0/1/2 10/19/4
Prior treatment surgery 10
radiotherapy 17
none 6
Sites of disease: primary tumour 8
(including local recurrence)
lymph nodes 20
lung 9
liver 6
bone 5
skin I
patients developed grade 2/3 skin toxicity after 2 and 3 weeks
respectively). Therefore 29 patients were evaluable for res-
ponse. All 33 patients were considered evaluable for toxicity.
The median duration of treatment was 8 weeks (range 3-47).
Of the 29 evaluation patients, one patient with extensive
lymph node metastases achieved a complete response, of
19+ weeks duration, and ten patients achieved a partial
response, with a median response duration of 22 weeks
(range 16-48), for a total response rate of 38% (95% con-
fidence interval 20-56). Sites of response were; lung 5, liver
1, lymph nodes 6 and primary 1. Ten patients had NC at 8
weeks, of whom seven were kept on PTX for a median of 15
weeks (range 9-18), and seven patients had progressive
disease.
Thirteen patients were crossed over to cisplatin based
chemotherapy, cisplatin/methotrexate (DDP/MTX) (Yagoda,
1987); of these one achieved a CR, four a PR, three had NC,
and four had PD. One patient was not evaluable. Of these
five responders on DDP/MTX, one had initially also res-
ponded to PTX, one had NC at 8 weeks, and two had
progressed during PTX treatment. The fifth patient was not
evaluable to response due to grade 4 leucopenia at 3 weeks
and subsequent cessation of PTX treatment.
Toxicity
The most frequent toxicities are listed in Table II. The major
toxicities were leukopenia and thrombocytopenia, which
however were manageable and rapidly reversible; recovery
from nadir was usually reached within a few days after
treatment interruption and never required more than 7 days.
There were no episodes of bleeding or leucopenic fever. In six
patients grade 3-4 myelotoxicity developed quite suddenly
Table II Toxicity
Grade (WHO)
Worst toxicity observed 0 1 2 3 4
Leucocytes 9 7 13 3 1
Platelets 17 1 6 6 3
Nausea/vomiting 16 9 8 0 0
Skin 30 1 1 1 0
Pulmonary 32 0 1 0 0
Renal 31 2 0 0 0
Liver 32 0 1 0 0
within 1 treatment week, after preceding grade 0-1 toxicity,
whereas spontaneous recovery from grade 1 toxicity without
simultaneous dose adjustment was also observed. This neces-
sitated continuation ofweekly determination of blood counts
and appropriate dose adjustments. Three patients developed
a maculo-papular rash within the first weeks of treatment,
that required cessation of PTX treatment in two cases. These
skin rashes resolved completely within days after PTX was
stopped. No mucositis was observed. Mild nausea and vomit-
ing was seen occasionally in 52% of the patients, and only a
minority of patients used anti-emetic drugs at regular inter-
vals. There was one case of dyspnea and evidence of intersti-
tial pulmonary changes, which were reversible upon cessation
of treatment and was attributed to PTX. The clinical details
of this patient are in press elsewhere (De Wit et al., 1992). In
three patients we noted the development of low grade hemo-
lytic anaemia during the course of treatment that was rapidly
reversible upon cessation of PTX. An example is shown in
Figure 1. To our knowledge this side effect has not been
reported previously. Dose escalation was performed only in
three patients. In view of the myelotoxicity observed in the
first five patients, no further dose escalations were performed.
A one step dose reduction was performed in 13 patients, and
a second step was made in seven patients.
Discussion
Presently, DDP and MTX are the most commonly used
single agents in the treatment of advanced transitional cell
cancer of the urothelial tract, with average response rates of
24% in 629 patients and 29% in 236 patients, respectively.
The responses were usually partial and of short duration
(median 3 to 6 months) (Yagoda, 1987; Oliver et al., 1986;
Khandekar et al., 1985; Troner et al., 1987; Hillcoat et al.,
1989; Loehrer et al., 1990). In an attempt to improve the
results various combinations of DDP and MTX with or
/ \-
/,
X , \~~~~~~~~~~~~~~
f ,, X~~~~
OCT NOV DEC JAN '92
Figure 1 An example of hemolysis during PTX treatment, black arrows indicate blood transfusions (units of packed cells).
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without other agents have been studied. Although with com-
bination chemotherapy response rates have increased to
40-70%, the median duration of response and survival is
still less than 1 year, whereas such intensive combination
chemotherapy is at the cost ofconsiderable toxicity (Oliver et
al., 1986; Khandekar et al., 1985; Troner et al., 1987; Hill-
coat et al., 1989; Loehrer et al., 1990; Stoter et al., 1987;
Harker et al., 1985; Yagoda, 1989; Stemnberg et al., 1989;
Logothetis et al., 1990a, b). Apart from the limited efficacy of
the currently available agents, intercurrent disease in this
usually elderly population may preclude treatment with drugs
such as cisplatin and methotrexate due to renal insufficiency,
or doxorubicin due to cardiac disease. These factors warrant
the search for new effective agents (even in first-line treat-
ment). This phase II study investigated the clinical usefulness
of PTX, a new lipid-soluble dihydrofolate reductase inhibi-
tor, in patients with advanced urothelial cancer. Our results
reported here indicate that PTX administered in a 5-day,
low-dose oral schedule is active in urothelial cancer. Of 29
evaluable patients treated with PTX, one achieved a CR and
10 a PR, with a median response duration of 22 weeks, for a
total response rate of 38% (95% confidence interval 20-56).
When the non-evaluable patients are included in the analysis,
the overall response rate is 33%. This response rate is similar
to that for the parent compound methotrexate: 29% (95%
confidence interval 23-35%).
PTX was generally well tolerated. The major toxicity was
myelosuppression. Other toxicities included skin rash that
required early cessation of PTX treatment in two cases, and
mild nausea and vomiting. Three patients developed hemo-
lytic anaemia during treatment, and one patient developed
reversible interstitial pulmonary changes, that were attributed
to PTX. In several patients we observed the sudden develop-
ment of myelotoxicity, after prolonged treatment periods
without significant previous myelotoxicity, whereas other
patients demonstrated spontaneous recovery from grade 1
toxicity despite treatment continuation. This may be indica-
tive of intra-patient variability of drug resorption, and
because of its unpredictable nature necessitated weekly deter-
minations of blood counts (Weiss et al., 1989). Without
exceptions all side-effects were rapidly reversible after discon-
tinuation of drug administration.
In conclusion, PTX appears to be an active agent in
patients with advanced urothelial cancer when administered
as a 5-day, low-dose oral schedule. Furthermore, the drug is
well tolerated with myelosuppression as the major toxicity,
that is sometimes unpredictable and frequently requires dose
modification. It would be attractive to investigate the com-
bination of PTX and cisplatin.
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